2021 ´ëÇѽÅÀåÇÐȸ È£³²Áöȸ ½ÉÆ÷Áö¾ö : 2021-12-02±³À°ÀÏÀÚ : 2021-12-02
±³À°Àå¼Ò : ÀüºÏ´ëÇб³º´¿ø Àӻ󿬱¸Áö¿ø¼¾ÅÍ 1Ãþ ¼¼¹Ì³ª½Ç
±³À°ÁÖÁ¦ :
2021 ´ëÇѽÅÀåÇÐȸ È£³²Áöȸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : È£³² Áöȸ
´ã´çÀÚ : ±è⼺
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
laminion@hanmail.net ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
Àü¶óºÏµµ±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 16:00~16:15 Clinical characteristics of acute kidney injury in patients with glyphosate surfactant herbicide intoxication Á¶¾Æ¿µ(ÀüÁÖ¿¹¼öº´¿ø)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 16:15~16:30 Potassium intake, blood pressure variability and cardiovascular outcomes in chronic kidney disease ¼»óÇå(Àü³²ÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 16:30~16:45 Light chain deposition disease in kidney transplantation ½Åº´Ã¶(Á¶¼±ÀÇ´ë)
Åä·Ð 12-02 ¼¼¹Ì³ª½Ç 16:45~17:00 ÆгÎÅäÀÇ(ÁÖÁ¦: Clinical outcomes of chronic kidney disease) À̽Ä,±è⼺,ÃÖÈ«»ó(ÀüºÏÀÇ´ë,Àü³²ÀÇ´ë,Àü³²ÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 17:00~17:20 Effects of probiotics, prebiotics, and synbiotics on uremic toxins, inflammation and oxidative stress in HD patients ±èÇü¿Ï(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 17:20~17:40 Plasma sclerostin level associated with use of MCO dialyzer in ESRD patients (2 year study) Á¤Á¾È¯(¿ø±¤ÀÇ´ë)
Åä·Ð 12-02 ¼¼¹Ì³ª½Ç 17:40~18:00 ÆгÎÅäÀÇ(ÁÖÁ¦: Biomarkers of ESRD) ±èÇö¸®,¹èÀºÈñ,¿ÀÅ·Å(Á¶¼±ÀÇ´ë,Àü³²ÀÇ´ë,Àü³²ÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 18:00~18:25 ¿ä¾çº´¿ø¿¡¼ Åõ¼® ȯÀÚº¸±â ¼ÛÁÖÈ«(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 18:25~18:50 ¸ð¹ü»ýº¸´Ù ¸ðÇè»ýÀ» ¹Ú¼º±¤(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 12-02 ¼¼¹Ì³ª½Ç 18:50~19:15 God committee/David & Goliath À̱¤¿µ(ÀüÁÖ¿¹¼öº´¿ø)
Åä·Ð 12-02 ¼¼¹Ì³ª½Ç 19:15~19:30 ÆгÎÅäÀÇ(ÁÖÁ¦: Emerging problems of ethical conflict) ¾È¼±È£,°°æÇ¥,¼±ÀοÀ(¿ø±¤ÀÇ´ë,ÀüºÏÀÇ´ë,ÀüÁÖ¿¹¼öº´¿ø)